Investors & News

Stay Up to Date with Notitia's Latest Clinical Trials and Other Developments

Our News

Notitia Biotechnologies Unveils Groundbreaking Microbiome Discovery: A Core Microbiome Signature as a New Health Indicator

Monmouth Junction, NJ, October 7th , 2024 – Notitia Biotechnologies, a leader in microbiome-based therapies, announces the publication of a pivotal study in Cell (2024) by its co-founder, Dr. Liping Zhao, and an international team of collaborators. This landmark research identifies a "Core Microbiome Signature" composed of two key groups of bacteria—the Foundation Guild™ and Pathobiont Guild—which serve as crucial indicators of gut health.

Utilizing the proprietary Two Competing Guilds (TCG) model, the study reveals a dynamic "seesaw" relationship between these bacterial groups, enabling accurate prediction of individual health status across various demographics. This discovery opens new avenues for personalized medicine, microbiome restoration therapies, and next-generation health diagnostics.

Empowering Health Through Gut Microbiome Analysis

At the heart of this breakthrough discovery is the Foundation Guild, a group of beneficial bacteria responsible for fiber fermentation and producing short-chain fatty acids (SCFAs), essential for metabolic and immune health. The Pathobiont Guild, in contrast, includes bacteria associated with inflammation and disease.

“This study provides scientific validation for our novel microbiome therapy, which aims to restore the balance between these two bacterial guilds to enhance health and prevent disease,” says Jeffrey Zhao, CEO of Notitia Biotechnologies. “Our innovative approach is setting new standards for gut microbiome therapies and disease prevention.”

Targeted Nutrition and Dietary Products: Enhancing the Foundation Guild

Building on this groundbreaking discovery, Notitia is expanding its research into targeted nutrition to promote the growth of the Foundation Guild bacteria. The company’s existing microbiome nutrition product, Guild:Plus, plays a key role in this effort. Guild:Plus is specifically designed to nurture Foundation Guild bacteria through a blend of prebiotics and fibers known to enhance their function, helping to restore gut health in individuals experiencing dysbiosis or imbalance in their microbiota.

Dr. Liping Zhao adds, “Our product development is focused on creating precision nutrition solutions that target the Foundation Guild. Through targeted dietary interventions, such as Guild:Plus, we aim to enrich the beneficial bacteria essential for gut health. These products will give consumers a powerful tool for promoting a healthy microbiome.”

Redefining Health with the Two Competing Guilds Model

Dr. Zhao’s research directly applies to Notitia’s therapeutic pipeline, including the company’s NBT-NM108 and pipelines of other novel microbiome therapies aiming to treat conditions associated with gut dysbiosis. These products are undergoing clinical trials, with plans to demonstrate their potential to address chronic diseases such as type 2 diabetes, inflammatory bowel disease, and more.

“We are advancing the frontier of microbiome science,” Dr. Zhao explains. “By understanding the core microbiome signature, we hope to develop more effective treatments to alleviate a wide range of diseases.”

Nutrition and Health: A Vision for the Future

With the addition of targeted nutrition products like Guild:Plus, Notitia is transforming how the microbiome can be supported through everyday dietary choices. By leveraging insights from the TCG model, Notitia’s products promote the specific growth of health- promoting bacterial guilds while suppressing pathogenic microbes. The ongoing development of these dietary products reflects Notitia’s commitment to improving health outcomes through accessible, nutrition-based solutions.

This breakthrough will be the focus of several upcoming research initiatives and collaborations, with detailed findings and product innovations available on the company’s website.

Notitia Biotechnologies Announces Early Completion of Phase 2 Study COVGUT20 for NBT- NM108

Trial Hits Primary Endpoint Ahead of Schedule: NBT-NM108 Demonstrates Potent Promotion of Foundation Guild™ Bacteria

Monmouth Junction, NJ – July 3rd , 2024 – Notitia Biotechnologies is proud to announce the early completion of its Phase 2 clinical trial COVGUT20 for the investigational drug NBT-NM108. The trial achieved its primary endpoint ahead of schedule, demonstrating that NBT-NM108 effectively promotes the gut bacteria Amplicon Sequence Variants (ASVs) that are members of the Foundation Guild, a core component of the human microbiome essential for gut health.

The COVGUT20 study was designed to assess whether NBT-NM108 could support the growth of these beneficial bacteria, critical for gut microbiota balance and the alleviation of gut dysbiosis, a condition commonly linked to severe gastrointestinal and metabolic disorders. The study randomized participants into treatment and control groups, and those receiving NBT-NM108 displayed a significant increase in the targeted SCFA-producing bacteria, which are part of the Foundation Guild.

“The successful promotion of Foundation Guild bacteria underpins our approach of restoring gut health through ecological balance,” said Dr. Liping Zhao, Co-Founder and Chief Scientific Officer of Notitia Biotechnologies. “The fact that we completed the study ahead of schedule highlights the strong efficacy of NBT-NM108, bringing us closer to offering a groundbreaking treatment for microbiome-related diseases.”

Primary Endpoint: Restoration of Foundation Guild Bacteria

NBT-NM108 is a fiber-based investigational new drug designed to modulate the gut microbiome, specifically targeting and enriching Foundation Guild bacteria. These bacteria play a key role in promoting the production of short-chain fatty acids (SCFAs), crucial for maintaining gut health. The study showed that patients in the treatment arm had a statistically significant increase in these SCFA-producing bacteria, which are known to suppress harmful microbes and support overall gut stability.

Positive Implications for COVID-19 and Other Conditions

The COVGUT20 study was initially launched to explore whether NBT-NM108 could alleviate gut- related complications in patients with COVID-19, but the results suggest broader applications. “By promoting the growth of Foundation Guild bacteria, we are advancing a universal solution for treating gut dysbiosis, which can manifest in multiple diseases including metabolic and inflammatory conditions,” added CEO Gongze "Jeffrey" Zhao.

Looking Forward

With the successful completion of the COVGUT20 study, Notitia is preparing for later-stage trials to further validate NBT-NM108’s efficacy and safety. The company is also exploring additional indications where restoring the Foundation Guild microbiota can improve patient outcomes.

Notitia Biotechnologies Company Announces Expansion of Study Population for COVID-19 Phase 2 Study (COVGUT20) for NBT-NM108

April 28, 2021

Monmouth Junction, NJ – 4/28/2021 – After months of preparation, Notitia Biotechnologies Company (Notitia) announced that its COVID-19 Phase 2 study (COVGUT20) for NBT-NM108 has been given support by the Food and Drug Administration (FDA) to expand its study population to all symptomatic COVID-19 patients.

"Previously, our trial focused on COVID-19 patients with type 2 diabetes and prediabetes. Now with this timely expansion to our study population, we can help more people and test NBT- NM108’s efficacy not just for diabetic patients, but for anyone with COVID-19 symptoms,” said Jeffrey Zhao, Co-founder and CEO at Notitia.

NBT-NM108 was created by Rutgers University professor Dr. Liping Zhao and was given the Investigational New Drug status by the FDA as a potential treatment for early-stage COVID-19. The botanical-based formula works to prevent severe complications and hospitalizations in COVID-19 patients by increasing the beneficial bacteria in the gut and reducing overall inflammation in the body.

Previous studies have also found that the beneficial bacteria in the gut can also produce short-chain fatty acids (SCFAs), critical to the hosts’ antiviral immunity. NBT-NM108 can significantly increase the SCFAs in the body and reduce inflammation caused by the dangerous pathogens in the gut.

“Overgrowth of opportunistic pathogens in the gut has been shown to drive a more severe form of COVID-19. Such pathogens can contribute to the cytokine storm and sepsis, which are the major causes of mortality in COVID-19 patients,” said Dr. Zhao, professor and Eveleigh-Fenton Chair of Applied Microbiology of the Department of Biochemistry and Microbiology at the School of Environmental and Biological Sciences.

Notitia is working with collaborators from Rutgers University and the University of South Florida to recruit patients in New Jersey and Florida who have either tested positive for coronavirus or are awaiting test results and are within seven days of onset of COVID-19 symptoms.

Compared to other drugs and therapies, NBT-NM108 does not target the virus itself, making it suitable for all COVID-19 variants. It can also be self-administered by patients at home, and it is also safer than other drugs, thanks to its naturally based botanical formulation.

To sign up for the clinical trial, patients can visit https://notitia.studyenrollment.com, the study is also registered on clinicaltrials.gov under the access number NCT04540406.

About Notitia Biotechnologies Company:

Notitia Biotechnologies Company (Notitia) is a next-generation microbiome biotherapeutic company that unlocks gut microbiome data to develop innovative products and therapies for patients and the general public. The company uses a proprietary reference-free Foundation Guild R&D platform to discover novel bacterial players and create products focused on ecologically restoring the gut ecosystem. Based near Princeton, New Jersey, the company was founded in 2019 by Jeffrey Zhao, Chief Executive Officer, and Dr. Liping Zhao. To learn more, please visit https://www.notitiabio.com

Rutgers Researcher Invents Microbiota Formula to Help High-Risk Patients Fight COVID-19

February 5, 2021

A Rutgers scientist has invented an early treatment for COVID-19 to prevent severe complications and hospitalizations in patients with prediabetes and diabetes by increasing beneficial bacteria in the gut and reducing organisms that cause coronavirus.

The treatment – created by researcher Liping Zhao – was given the Investigational New Drug status by the Food and Drug Administration and will start Phase 2a trial Feb. 8. While the treatment, NBT-NM108, does not target the coronavirus directly, it does help to create stable foundation for a healthy digestive tract.

“COVID-19 patients with pre-existing conditions such as obesity and type 2 diabetes suffer three to four times higher mortality rate than the average patient population,” said Zhao, professor and Eveleigh-Fenton Chair of Applied Microbiology of the Department of Biochemistry and Microbiology at the School of Environmental and Biological Sciences. “Overgrowth of opportunistic pathogens in the gut of diabetic or prediabetic patients may drive the more severe form of COVID-19. Such pathogens can contribute to the cytokine storm and sepsis, which are the major causes of mortality in these high-risk patients.”

Researchers will begin recruiting patients with diabetes and prediabetes who have tested positive for coronavirus, or are awaiting test results, and are within seven days of onset of COVID-19 symptoms. They hope to have results from the initial study by April.

Zhao has shown in previous studies that proper microbiome nutrition can increase good bacteria in the digestive track of those with type 2 diabetes. When good bacteria were restored, opportunistic pathogens in the gut were reduced to low levels. While the new treatment does not directly target the coronavirus, the scientists believe that a reduction of these pathogens may lead to decreased levels of inflammation and also reduce risk for complications such as bacterial sepsis.

“Controlling the gut microbiota in a way that doesn’t allow the overgrowth of pathogens in the gut could become a very important component of the COVID-19 care,” said Zhao.

The participants for the clinical trial will be recruited by the University of South Florida as part of a collaboration and partnership with Rutgers. The day-to-day measurements and samples will be handled by Liping Zhao’s Lab at Rutgers through an online patient managing platform. The early treatment of the gut microbiota with Zhao’s formula will be a home-based intervention for patients with mild to moderate symptoms.

This clinical trial is sponsored by a Rutgers startup, Notitia Biotechnologies, a next-generation microbiome biotherapeutic company that develops innovative products for patients and the general public.

“We have the vision that everyone can live a long and healthy life by keeping our gut microbiome to the healthiest possible status for the longest possible time. Notitia’s mission is to help everyone achieve a healthy gut microbiota by protecting or restoring the foundation guild of the gut microbial forest,” said Jeffery Zhao, cofounder and CEO of Notitia Biotechnologies.

Notitia Biotechnologies Receives Approval from FDA for Phase 2a Clinical Trial in Diabetic & Prediabetic Patients

August 14, 2020

Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient's gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a randomized, controlled clinical trial, and the study will be performed in the Tampa Florida area. Enrollment is expected to begin by October, and further information regarding the study is available on clinicaltrials.gov.

For more information regarding Notitia's Foundation Guild Microbiome R&D Platform, please click here. For more information about the NBT-NM108's development pipeline, please click here.

Notitia Biotechnologies Develops Revolutionary Foundation Guild LBP for Patients with Diabetic Kidney Disease (DKD)

June 24, 2020

Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format.

Notitia is preparing the Investigational New Drug (IND) application to the FDA to start a Phase 1/2 combined clinical trial in Q1 2021. For more information regarding Notitia's Foundation Guild Microbiome R&D Platform, please click here. For more information about the NBT-BM306's development pipeline, please click here.

Go to top